- Home
- KVHI vs CHRS Comparison
KVHI vs CHRS Comparison
Compare KVHI & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KVHI
- CHRS
- Stock Information
- Founded
- KVHI 1978
- CHRS 2010
- Country
- KVHI United States
- CHRS United States
- Employees
- KVHI N/A
- CHRS N/A
- Industry
- KVHI Radio And Television Broadcasting And Communications Equipment
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KVHI Technology
- CHRS Health Care
- Exchange
- KVHI Nasdaq
- CHRS Nasdaq
- Market Cap
- KVHI 101.7M
- CHRS 112.5M
- IPO Year
- KVHI 1996
- CHRS 2014
- Fundamental
- Price
- KVHI $5.30
- CHRS $0.77
- Analyst Decision
- KVHI
- CHRS Buy
- Analyst Count
- KVHI 0
- CHRS 3
- Target Price
- KVHI N/A
- CHRS $4.68
- AVG Volume (30 Days)
- KVHI 33.1K
- CHRS 1.5M
- Earning Date
- KVHI 05-07-2025
- CHRS 05-12-2025
- Dividend Yield
- KVHI N/A
- CHRS N/A
- EPS Growth
- KVHI N/A
- CHRS N/A
- EPS
- KVHI N/A
- CHRS N/A
- Revenue
- KVHI $109,975,000.00
- CHRS $272,251,000.00
- Revenue This Year
- KVHI $4.22
- CHRS N/A
- Revenue Next Year
- KVHI $13.27
- CHRS $19.78
- P/E Ratio
- KVHI N/A
- CHRS $1.83
- Revenue Growth
- KVHI N/A
- CHRS 19.87
- 52 Week Low
- KVHI $4.17
- CHRS $0.66
- 52 Week High
- KVHI $6.16
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- KVHI 62.40
- CHRS 39.42
- Support Level
- KVHI $5.36
- CHRS $0.74
- Resistance Level
- KVHI $5.60
- CHRS $0.82
- Average True Range (ATR)
- KVHI 0.18
- CHRS 0.06
- MACD
- KVHI 0.03
- CHRS -0.00
- Stochastic Oscillator
- KVHI 67.69
- CHRS 23.41
About KVHI KVH Industries Inc.
KVH Industries Inc provides integrated, end-to-end services, software, and hardware that support its customers' need for access to the Internet, VoIP, operations content, and entertainment services. It offers high-speed Internet and Voice over Internet Protocol (VoIP) services via satellite and integrated 5G/LTE cellular communications to mobile users at sea and on land. The company also provides commercially licensed entertainment, including news, sports, music, and movies, to commercial and leisure customers in the maritime, hotel, and retail markets. It operates in several geographic areas, including internationally. Revenues are generated from international locations, mainly consisting of Singapore, Canada, South America, European Union and other European countries, and other regions.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.